{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:19:42Z","timestamp":1792174782267,"version":"4.4.0"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1079351"],"award-info":[{"award-number":["APP1079351"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1117602"],"award-info":[{"award-number":["APP1117602"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1155527"],"award-info":[{"award-number":["APP1155527"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1059960"],"award-info":[{"award-number":["APP1059960"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1120853"],"award-info":[{"award-number":["APP1120853"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1025581"],"award-info":[{"award-number":["APP1025581"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["361646"],"award-info":[{"award-number":["361646"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2023.115989","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T11:36:53Z","timestamp":1701085013000},"page":"115989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists"],"prefix":"10.1016","volume":"265","author":[{"given":"Xiangyan","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jephthah O.","family":"Odiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Xue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8610-0058","authenticated-orcid":false,"given":"Rebecca H.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2114-8242","authenticated-orcid":false,"given":"Jonathan B.","family":"Baell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115989_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113167","article-title":"Recent advances in the design and development of formyl peptide receptor 2 (FPR2\/ALX) agonists as pro-resolving agents with diverse therapeutic potential","volume":"213","author":"Maciuszek","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/jphp.12811","article-title":"Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases","volume":"70","author":"Szollosi","year":"2017","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejphar.2018.06.025","article-title":"Targeting formyl peptide receptors to facilitate the resolution of inflammation","volume":"833","author":"Filep","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib4","article-title":"5-lipoxygenase pathway, dendritic cells, and adaptive immunity","volume":"2004","author":"Hedi","year":"2004","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejmech.2023.115989_bib5","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/ijms18122539","article-title":"Prostaglandin E2 in the regulation of water transport in renal collecting ducts","volume":"18","author":"Li","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.14530","article-title":"Prostaglandin-cytokine crosstalk in chronic inflammation","volume":"176","author":"Yao","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1146\/annurev-pharmtox-051821-042743","article-title":"Resolution pharmacology: focus on pro-resolving Annexin A1 and lipid mediators for therapeutic innovation in inflammation","volume":"63","author":"Perretti","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115989_bib8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1080\/13543776.2016.1216546","article-title":"Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2012-2015)","volume":"26","author":"Tsai","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2023.115989_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1021\/jm501051x","article-title":"FPR2\/ALXR agonists and the resolution of inflammation","volume":"58","author":"Corminboeuf","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib10","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1111\/bph.15212","article-title":"Formyl peptide receptor type 2 agonists to kick-start resolution pharmacology","volume":"177","author":"Perretti","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib11","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1111\/bph.15919","article-title":"Formylpeptide receptor 2: nomenclature, structure, signalling and translational perspectives: IUPHAR review 35","volume":"179","author":"Qin","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14232","article-title":"Small-molecule-biased formyl peptide receptor agonist compound 17b protects against myocardial ischaemia-reperfusion injury in mice","volume":"8","author":"Qin","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib13","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1021\/acs.jmedchem.9b02101","article-title":"Discovery oF BMS-986235\/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure","volume":"63","author":"Asahina","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jalz.2013.12.024","article-title":"Resolution of inflammation is altered in Alzheimer's disease","volume":"11","author":"Wang","year":"2015","journal-title":"Alzheimers. Dement."},{"key":"10.1016\/j.ejmech.2023.115989_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12974-016-0540-8","article-title":"Lipoxin A4 inhibits microglial activation and reduces neuroinflammation and neuropathic pain after spinal cord hemisection","volume":"13","author":"Martini","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2023.115989_bib16","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3390\/nu13051418","article-title":"Formyl peptide receptor (FPR)1 modulation by resveratrol in an LPS-induced neuroinflammatory animal model","volume":"13","author":"Calvello","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.ejmech.2023.115989_bib17","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nrrheum.2012.166","article-title":"The multiple facets of glucocorticoid action in rheumatoid arthritis","volume":"8","author":"Baschant","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2023.115989_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nrrheum.2013.126","article-title":"Annexin A1: potential for glucocorticoid sparing in RA","volume":"9","author":"Yang","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejmech.2023.115989_bib19","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1111\/bph.12768","article-title":"A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis","volume":"171","author":"Kao","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.intimp.2018.05.028","article-title":"Formyl peptide receptor activation inhibits the expansion of effector T cells and synovial fibroblasts and attenuates joint injury in models of rheumatoid arthritis","volume":"61","author":"Odobasic","year":"2018","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115989_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10753-014-9819-z","article-title":"Formyl peptide receptor suppresses melanoma development and promotes NK cell migration","volume":"37","author":"Liu","year":"2014","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2023.115989_bib22","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.it.2018.08.005","article-title":"Formyl-peptide receptors in infection, inflammation, and cancer","volume":"39","author":"Wei\u00df","year":"2018","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1158\/0008-5472.CAN-12-2290","article-title":"Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pharmthera.2013.07.007","article-title":"Treating neutrophilic inflammation in COPD by targeting ALX\/FPR2 resolution pathways","volume":"140","author":"Bozinovski","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115989_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.intimp.2018.08.011","article-title":"Mimetic peptide Ac2-26 of Annexin A1 as a potential therapeutic agent to treat COPD","volume":"63","author":"Possebon","year":"2018","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejmech.2023.115989_bib26","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2337\/db18-0469","article-title":"FPR2 deficiency alleviates diet-induced insulin resistance through reducing body weight gain and inhibiting inflammation mediated by macrophage chemotaxis and M1 polarization","volume":"68","author":"Chen","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2023.115989_bib27","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fimmu.2019.00938","article-title":"Annexin-A1: therapeutic potential in microvascular disease","volume":"10","author":"Purvis","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/molecules22030455","article-title":"The formyl peptide receptors: diversity of ligands and mechanism for recognition","volume":"22","author":"He","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2023.115989_bib29","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, Paralogon groups, and Fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib30","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/pr.109.001578","article-title":"International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family","volume":"61","author":"Ye","year":"2009","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2023.115989_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0888-7543(92)90265-T","article-title":"Mapping of genes for the human C5A receptor (C5AR), human fmlp receptor (FPR), and two fmlp receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19","volume":"13","author":"Bao","year":"1992","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2023.115989_bib32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.cytogfr.2006.09.009","article-title":"Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses","volume":"17","author":"Migeotte","year":"2006","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2023.115989_bib33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bcpt.12903","article-title":"Formyl peptide receptors in mice and men: similarities and differences in recognition of conventional ligands and modulating lipopeptides","volume":"122","author":"Winther","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115989_bib34","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1006\/geno.1998.5376","article-title":"Differential expansion of the N-formylpeptide receptor gene cluster in human and mouse","volume":"51","author":"Gao","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2023.115989_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/mol.112.081315","article-title":"Functional characterization of three mouse formyl peptide receptors","volume":"83","author":"He","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib36","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1074\/jbc.M113.509216","article-title":"Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands","volume":"289","author":"He","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib37","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.4049\/jimmunol.181.2.1429","article-title":"Identification of formyl peptides from listeria monocytogenes and staphylococcus aureus as potent chemoattractants for mouse neutrophils1","volume":"181","author":"Southgate","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib38","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4049\/jimmunol.0903022","article-title":"Cutting edge: a critical role for the G protein-coupled receptor mFPR2 in airway inflammation and immune responses","volume":"184","author":"Chen","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib39","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s43440-021-00271-x","article-title":"Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology","volume":"73","author":"Tylek","year":"2021","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.ejmech.2023.115989_bib40","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1021\/bi00552a019","article-title":"Further studies on the structural requirements for synthetic peptide chemoattractants","volume":"19","author":"Freer","year":"1980","journal-title":"Biochemist"},{"key":"10.1016\/j.ejmech.2023.115989_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI13430","article-title":"A proinflammatory peptide from helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis","volume":"108","author":"Betten","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2023.115989_bib42","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbrc.2010.12.007","article-title":"Mitocryptide-2, a neutrophil-activating cryptide, is a specific endogenous agonist for formyl-peptide receptor-like 1","volume":"404","author":"Seki","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib43","doi-asserted-by":"crossref","first-page":"23645","DOI":"10.1074\/jbc.M101031200","article-title":"Amyloid-\u03b2; induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a g protein-coupled receptor expressed in phagocytes and brain","volume":"276","author":"Tiffany","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib44","doi-asserted-by":"crossref","first-page":"RC123","DOI":"10.1523\/JNEUROSCI.21-02-j0003.2001","article-title":"Amyloid \u03b242 activates a G-protein-coupled chemoattractant receptor, FPR-like-1","volume":"21","author":"Le","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115989_bib45","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1084\/jem.189.2.395","article-title":"A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells","volume":"189","author":"Su","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib46","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1073\/pnas.1322357111","article-title":"Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis","volume":"111","author":"Lu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115989_bib47","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood-2005-08-3099","article-title":"Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement","volume":"107","author":"Hayhoe","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2023.115989_bib48","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020385118","article-title":"Annexin A1 attenuates cardiac diastolic dysfunction in mice with inflammatory arthritis","volume":"118","author":"Chen","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115989_bib49","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1152\/physrev.00030.2001","article-title":"Annexins: from structure to function","volume":"82","author":"Gerke","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115989_bib50","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/nm786","article-title":"Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor","volume":"8","author":"Perretti","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2014.11.012","article-title":"Cardioprotective potential of Annexin-A1 mimetics in myocardial infarction","volume":"148","author":"Qin","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.115989_bib52","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.180.1.253","article-title":"Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor","volume":"180","author":"Fiore","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib53","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.185.9.1693","article-title":"Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors","volume":"185","author":"Takano","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib54","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev-pharmtox-051921-085407","article-title":"Lipoxin mimetics and the resolution of inflammation","volume":"63","author":"Godson","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115989_bib55","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1476-5381.2009.00386.x","article-title":"Lipoxins: resolutionary road","volume":"158","author":"Maderna","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2015.05.003","article-title":"Lipoxin A4 attenuates obesity-induced adipose inflammation and associated liver and kidney disease","volume":"22","author":"B\u00f6rgeson","year":"2015","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2023.115989_bib57","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.bjp.0705912","article-title":"Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration","volume":"143","author":"Bannenberg","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib58","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1021\/jm030569l","article-title":"Novel 3-oxa lipoxin A4 analogues with enhanced chemical and metabolic stability have anti-inflammatory activity in vivo","volume":"47","author":"Guilford","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib59","doi-asserted-by":"crossref","first-page":"9193","DOI":"10.1021\/acs.jmedchem.1c00403","article-title":"Asymmetric synthesis and biological screening of quinoxaline-containing synthetic lipoxin A4 mimetics (QNX-sLXms)","volume":"64","author":"de Gaetano","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib60","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1073\/pnas.96.14.8247","article-title":"Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo","volume":"96","author":"Clish","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115989_bib61","doi-asserted-by":"crossref","first-page":"14609","DOI":"10.1021\/bi00044a041","article-title":"Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils","volume":"34","author":"Serhan","year":"1995","journal-title":"Biochemist"},{"key":"10.1016\/j.ejmech.2023.115989_bib62","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.2337\/db17-1317","article-title":"Lipoxins protect against inflammation in diabetes-associated atherosclerosis","volume":"67","author":"Brennan","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2023.115989_bib63","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejmech.2018.10.049","article-title":"Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin a4 mimetics (sLXms)","volume":"162","author":"de Gaetano","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib64","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.bmcl.2008.01.013","article-title":"Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties","volume":"18","author":"Petasis","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115989_bib65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1021\/acsptsci.9b00097","article-title":"Therapeutic potential of lipoxin A4 in chronic inflammation: focus on cardiometabolic disease","volume":"3","author":"Fu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib66","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.0907342107","article-title":"Resolvin D1 binds human phagocytes with evidence for proresolving receptors","volume":"107","author":"Krishnamoorthy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115989_bib67","first-page":"2362","article-title":"Resolvin D3 is dysregulated in arthritis and reduces arthritic inflammation","volume":"197","author":"Arnardottir","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib68","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137713","article-title":"Resolvin D1 supports skeletal myofiber regeneration via actions on myeloid and muscle stem cells","volume":"5","author":"Markworth","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejmech.2023.115989_bib69","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3389\/fphar.2018.01273","article-title":"Lipoxin and resolvin receptors transducing the resolution of inflammation in cardiovascular disease","volume":"9","author":"Pirault","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib70","doi-asserted-by":"crossref","first-page":"21585","DOI":"10.1074\/jbc.M007769200","article-title":"The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1\/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2","volume":"276","author":"Christophe","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib71","doi-asserted-by":"crossref","first-page":"7594","DOI":"10.1021\/bi982861e","article-title":"Lipoxin A4: a new class of ligand for the Ah receptor","volume":"38","author":"Schaldach","year":"1999","journal-title":"Biochemist"},{"key":"10.1016\/j.ejmech.2023.115989_bib72","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1096\/fj.11-187658","article-title":"Lipoxin A4 is a novel estrogen receptor modulator","volume":"25","author":"Russell","year":"2011","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2023.115989_bib73","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9440(10)63937-5","article-title":"Selectivity of recombinant human leukotriene D4, leukotriene B4, and lipoxin A4 receptors with aspirin-triggered 15-epi-LXA4 and regulation of vascular and inflammatory responses","volume":"158","author":"Gronert","year":"2001","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2023.115989_bib74","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41467-020-14728-9","article-title":"Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling","volume":"11","author":"Zhuang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib75","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41467-020-15009-1","article-title":"Structural basis of ligand binding modes at the human formyl peptide receptor 2","volume":"11","author":"Chen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib76","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1038\/s41467-022-32822-y","article-title":"Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns","volume":"13","author":"Chen","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib77","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/s41467-022-28586-0","article-title":"Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2","volume":"13","author":"Zhuang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib78","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41467-022-29361-x","article-title":"Structural basis of FPR2 in recognition of A\u03b242 and neuroprotection by humanin","volume":"13","author":"Zhu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.115989_bib79","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1021\/bi982274t","article-title":"Multiple activation steps of the N-formyl peptide receptor","volume":"38","author":"Prossnitz","year":"1999","journal-title":"Biochemist"},{"key":"10.1016\/j.ejmech.2023.115989_bib80","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1124\/mol.105.014068","article-title":"Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists","volume":"68","author":"Edwards","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib81","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1074\/jbc.M109.080465","article-title":"The Annexin I sequence Gln9-Ala10-Trp11-Phe12 is a core structure for interaction with the formyl peptide receptor 1","volume":"285","author":"Movitz","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib82","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1124\/mol.113.086595","article-title":"Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries","volume":"84","author":"Pinilla","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib83","doi-asserted-by":"crossref","first-page":"436","DOI":"10.2741\/e778","article-title":"The potential impacts of formyl peptide receptor 1 in inflammatory diseases","volume":"8","author":"Yang","year":"2016","journal-title":"Front. Biosci."},{"key":"10.1016\/j.ejmech.2023.115989_bib84","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0898-6568(00)00075-9","article-title":"Studies on fMLP-receptor interaction and signal transduction pathway by means of fMLP-OMe selective analogues","volume":"12","author":"Fabbri","year":"2000","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2023.115989_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2006.01.034","article-title":"Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils","volume":"534","author":"Selvatici","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib86","doi-asserted-by":"crossref","first-page":"616","DOI":"10.4049\/jimmunol.179.1.616","article-title":"Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation","volume":"179","author":"El Kebir","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00092","article-title":"Endogenous acute phase serum amyloid A lacks pro-inflammatory activity, contrasting the two recombinant variants that activate human neutrophils through different receptors","volume":"4","author":"Christenson","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/emmm.201000113","article-title":"Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK\/STAT\/SOCS signalling","volume":"3","author":"Pupjalis","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib89","doi-asserted-by":"crossref","first-page":"18232","DOI":"10.1073\/pnas.1308253110","article-title":"Ligand-specific conformational change of the G-protein-coupled receptor ALX\/FPR2 determines proresolving functional responses","volume":"110","author":"Cooray","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2023.115989_bib90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bbamcr.2018.11.015","article-title":"Biased perspectives on formyl peptide receptors","volume":"1866","author":"Raabe","year":"2019","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2023.115989_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115529","article-title":"AZ2158 is a more potent formyl peptide receptor 1 inhibitor than the commonly used peptide antagonists in abolishing neutrophil chemotaxis","volume":"211","author":"Forsman","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib92","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jaci.2007.01.015","article-title":"New molecular targets for the treatment of neutrophilic diseases","volume":"119","author":"Barnes","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.ejmech.2023.115989_bib93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nprot.2006.9","article-title":"Biomolecular screening of formylpeptide receptor ligands with a sensitive, quantitative, high-throughput flow cytometry platform","volume":"1","author":"Edwards","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2023.115989_bib94","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1084\/jem.191.7.1197","article-title":"Activation of lipoxin A4 receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation","volume":"191","author":"Chiang","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejmech.2023.115989_bib95","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1111\/bph.15811","article-title":"Community guidelines for GPCR ligand bias: IUPHAR review 32","volume":"179","author":"Kolb","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib96","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1161\/CIRCULATIONAHA.117.028194","article-title":"Biased G protein-coupled receptor signaling","volume":"137","author":"Wisler","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2023.115989_bib97","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tips.2007.06.006","article-title":"\u03b2-arrestin-biased ligands at seven-transmembrane receptors","volume":"28","author":"Violin","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib98","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2023.115989_bib99","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ceb.2013.11.010","article-title":"Functional selectivity of GPCR signaling in animals","volume":"27","author":"Zhou","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115989_bib100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ceb.2013.10.008","article-title":"Recent developments in biased agonism","volume":"27","author":"Wisler","year":"2014","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.ejmech.2023.115989_bib101","doi-asserted-by":"crossref","first-page":"14211","DOI":"10.1074\/jbc.M114.548131","article-title":"Divergent transducer-specific molecular efficacies generate biased agonism at a G protein-coupled receptor (GPCR)","volume":"289","author":"Strachan","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1124\/mol.106.028258","article-title":"An opioid agonist that does not induce \u03bc-opioid receptor-arrestin interactions or receptor internalization","volume":"71","author":"Groer","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib103","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: new frontiers in GPCR drug discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib104","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf7737","article-title":"Divergent acute versus prolonged pharmacological GLP-1R responses in adult \u03b2 cell-specific \u03b2-arrestin 2 knockout mice","volume":"9","author":"Bitsi","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2023.115989_bib105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4330\/wjc.v11.i2.47","article-title":"Not all arrestins are created equal: therapeutic implications of the functional diversity of the \u03b2-arrestins in the heart","volume":"11","author":"Lymperopoulos","year":"2019","journal-title":"World J. Cardiol."},{"key":"10.1016\/j.ejmech.2023.115989_bib106","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1021\/jm900592h","article-title":"6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors","volume":"52","author":"Cilibrizzi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ddr.21076","article-title":"Synthesis and pharmacological evaluation of new pyridazin-based thioderivatives as formyl peptide receptor (FPR) agonists","volume":"74","author":"Crocetti","year":"2013","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib108","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ejmech.2013.03.066","article-title":"Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRS) agonists","volume":"64","author":"Giovannoni","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ddr.21370","article-title":"Synthesis of five- and six-membered N-phenylacetamido substituted heterocycles as formyl peptide receptor agonists","volume":"78","author":"Vergelli","year":"2017","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib110","first-page":"2530","article-title":"2-arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists, Bioorg","volume":"24","author":"Vergelli","year":"2016","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib111","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/chir.22162","article-title":"Synthesis, HPLC enantioresolution, and X-ray analysis of a new series of C5-methyl pyridazines as N-formyl peptide receptor (FPR) agonists","volume":"25","author":"Cilibrizzi","year":"2013","journal-title":"Chirality"},{"key":"10.1016\/j.ejmech.2023.115989_bib112","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1016\/j.bmc.2012.04.043","article-title":"Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists","volume":"20","author":"Cilibrizzi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib113","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/chir.20227","article-title":"Enantioselective chromatography and absolute configuration of N, N-dimethyl-3-(naphthalen-2-yl)-butan-1-amines: potential sigma1 ligands","volume":"18","author":"Collina","year":"2006","journal-title":"Chirality"},{"key":"10.1016\/j.ejmech.2023.115989_bib114","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1021\/jm058042r","article-title":"Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach","volume":"48","author":"Cavalli","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/cbdd.13913","article-title":"Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists","volume":"98","author":"Vergelli","year":"2021","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2023.115989_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103880","article-title":"Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis","volume":"100","author":"Crocetti","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib117","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1021\/acs.jmedchem.8b01912","article-title":"Substituted pyridazin-3(2H)-ones as highly potent and biased formyl peptide receptor agonists","volume":"62","author":"Deora","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib118","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1021\/cn200111m","article-title":"A simple method for quantifying functional selectivity and agonist bias","volume":"3","author":"Kenakin","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2023.115989_bib119","series-title":"Phenyl Urea Analogs as Formyl Peptide Receptor 1 (FPR1) Selective Agonists","author":"Duong Tien","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115989_bib120","series-title":"Dihydronaphthalene and Naphthalene Derivatives as N-Formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Vuligonda","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib121","series-title":"Aryl Urea Derivatives as N-Formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib122","series-title":"Amide Derivatives of N-Urea Substituted Amino Acids as Formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib123","series-title":"Imidazolidine-2,4-dione Derivatives as N-Formyl Peptide Receptor 2 Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib124","series-title":"2,5-dioxoimidazolidin-1-yl-3-phenylurea Derivatives as Formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib125","series-title":"(2-ureidoacetamido)alkyl Derivatives as Formyl Peptide Receptor 2 Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib126","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/prot.22507","article-title":"GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex","volume":"78","author":"Katritch","year":"2010","journal-title":"Proteins: Struct., Funct., Bioinf."},{"key":"10.1016\/j.ejmech.2023.115989_bib127","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6807-10-8","article-title":"Forced unbinding of GPR17 ligands from wild type and R255I mutant receptor models through a computational approach","volume":"10","author":"Parravicini","year":"2010","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.ejmech.2023.115989_bib128","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1021\/jm900319e","article-title":"Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design","volume":"52","author":"Gloriam","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/mol.110.068288","article-title":"Gastrin-releasing peptide\/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors","volume":"79","author":"Schepetkin","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib130","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bcp.2012.11.015","article-title":"3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2","volume":"85","author":"Schepetkin","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib131","first-page":"3913","article-title":"Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2, Bioorg","volume":"23","author":"Lacivita","year":"2015","journal-title":"Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib132","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ejmech.2017.09.023","article-title":"Novel ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation","volume":"141","author":"Stama","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib133","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.1021\/jm201136z","article-title":"Structural modifications that alter the P-glycoprotein efflux properties of compounds","volume":"55","author":"Hitchcock","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib134","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1021\/acs.jmedchem.1c02203","article-title":"Design, synthesis, biological evaluation, and computational studies of novel ureidopropanamides as formyl peptide receptor 2 (FPR2) agonists to target the resolution of inflammation in central nervous system disorders","volume":"65","author":"Mastromarino","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1039\/C9MD00396G","article-title":"Scaffold-hopping as a strategy to address metabolic liabilities of aromatic compounds","volume":"11","author":"Lazzara","year":"2020","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104295","article-title":"Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure","volume":"146","author":"Kain","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib137","series-title":"Urea Derivative or Pharmacologically Acceptable Salt Thereof","author":"Takahashi","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113194","article-title":"Synthesis and evaluation of novel cyclopentane urea FPR2 agonists and their potential application in the treatment of cardiovascular inflammation","volume":"214","author":"Maciuszek","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib139","series-title":"Pharmaceutical Compositions Comprising 3,4- Dihydroisoquinolin-2(1h)-Yl-3-Phenylurea Derivatives Having Formyl Peptide Receptor Like-1 (FPRL-1) Agonist or Antagonist Activity","author":"Beard Richard","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib140","series-title":"Novel 1-(1-Oxo-1,2,3,4-Tetrahydroisoquinolin-7-Yl)urea Derivatives as N-Formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Beard Richard","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib141","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1016\/j.bmcl.2006.04.068","article-title":"Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents","volume":"16","author":"B\u00fcrli","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115989_bib142","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1254\/jphs.09196SC","article-title":"The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2\/ALX-selective agonist is instead an FPR1 and FPR2\/ALX dual agonist","volume":"111","author":"Sogawa","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib143","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1002\/ejoc.201601638","article-title":"Design of radioiodinated pharmaceuticals: structural features affecting metabolic stability towards in vivo deiodination","volume":"2017","author":"Cavina","year":"2017","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib144","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1021\/jp0457287","article-title":"Conformational analysis and rotational barriers of alkyl- and phenyl-substituted urea derivatives","volume":"109","author":"Bryantsev","year":"2005","journal-title":"J. Phys. Chem. A"},{"key":"10.1016\/j.ejmech.2023.115989_bib145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1254\/jphs.10194FP","article-title":"Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization","volume":"115","author":"Sogawa","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib146","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2567.2010.03367.x","article-title":"Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo","volume":"132","author":"Sogawa","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.ejmech.2023.115989_bib147","first-page":"905","article-title":"Preservation of post-infarction cardiac structure and function via long-term oral formyl peptide receptor agonist treatment","volume":"4","author":"Garc\u00eda","year":"2019","journal-title":"JACC (J. Am. Coll. Cardiol.): Basic Transl"},{"key":"10.1016\/j.ejmech.2023.115989_bib148","series-title":"Pyrazolone Formyl Peptide 2 Receptor Agonists","author":"Johnson James","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115989_bib149","series-title":"Piperidinone Formyl Peptide 2 Receptor and Formyl Peptide 1 Receptor Agonists","author":"Wurtz Nicholas","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115989_bib150","series-title":"Aryl Heterocyclic Piperidinone Formyl Peptide 2 Receptor and Formyl Peptide 1 Receptor Agonists","author":"Shirude Pravin","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib151","series-title":"Piperidinone Formyl Peptide 2 Receptor Agonists","author":"Shirude Pravin","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib152","series-title":"6-membered Cyclic Amines or Lactames Substituted with Urea and Phenyl","author":"Jakob","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib153","series-title":"Piperidines or Piperidones Substituted with Urea and Phenyl","author":"Jakob","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115989_bib154","series-title":"Piperidines or Piperidones Substituted with Urea and Heteroaryl","author":"Lesch","year":"2021"},{"key":"10.1016\/j.ejmech.2023.115989_bib155","series-title":"Urea Derivative or Pharmacologically Acceptable Salt Thereof","author":"Takahashi","year":"2015"},{"key":"10.1016\/j.ejmech.2023.115989_bib156","series-title":"Urea Derivative or Pharmacologically Acceptable Salt Thereof","author":"Fujii","year":"2016"},{"key":"10.1016\/j.ejmech.2023.115989_bib157","series-title":"Cyclopropyl Urea Formyl Peptide 2 Receptor and Formyl Peptide 1 Receptor Agonists","author":"Smallheer Joanne","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib158","series-title":"Oxopyrrolidine Urea FPR2 Agonists","author":"Shirude Pravin","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115989_bib159","series-title":"Phenylpyrrolidinone Formyl Peptide 2 Receptor Agonists","author":"Shirude Pravin","year":"2019"},{"key":"10.1016\/j.ejmech.2023.115989_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113805","article-title":"Design, synthesis, and biological evaluation of novel pyrrolidinone small-molecule formyl peptide receptor 2 agonists","volume":"226","author":"Maciuszek","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib161","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1124\/mol.109.060673","article-title":"Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition","volume":"77","author":"Kirpotina","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib162","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1039\/D1MD00058F","article-title":"Recent advances in urea- and thiourea-containing compounds: focus on innovative approaches in medicinal chemistry and organic synthesis","volume":"12","author":"Ronchetti","year":"2021","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib163","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1021\/acsmedchemlett.2c00079","article-title":"Discovery of heteroaryl urea isosteres for formyl peptide receptor 2 agonists","volume":"13","author":"Wurtz","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115989_bib164","series-title":"Pyrrolidinone Derivatives as Formyl Peptide 2 Receptor Agonists","author":"Wurtz","year":"2020"},{"key":"10.1016\/j.ejmech.2023.115989_bib165","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1349-7006.2006.00166.x","article-title":"Pharmacokinetics and pharmacodynamics of protein-unbound docetaxel in cancer patients","volume":"97","author":"Minami","year":"2006","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib166","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1158\/1078-0432.CCR-11-2684","article-title":"Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the \u03b3-secretase inhibitor RO4929097","volume":"18","author":"Wu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2023.115989_bib167","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejmech.2023.115989_bib168","series-title":"Aminopyrazole Derivatives","author":"Bur","year":"2009"},{"key":"10.1016\/j.ejmech.2023.115989_bib169","series-title":"Oxazole and Thiazole Derivatives as ALX Receptor Agonists","author":"Bur","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115989_bib170","series-title":"Aminotriazole Derivatives as ALX Agonists","author":"Bur","year":"2009"},{"key":"10.1016\/j.ejmech.2023.115989_bib171","series-title":"Hydroxylated Aminotriazole Derivatives as ALX Receptor Agonists","author":"Bur","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib172","series-title":"Oxazolyl-methylether Derivatives as ALX Receptor Agonists","author":"Bur","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib173","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/tx7002273","article-title":"Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism","volume":"21","author":"Baillie","year":"2008","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115989_bib174","series-title":"Fluorinated Aminotriazole Derivatives","author":"Bur","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115989_bib175","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1021\/tx0602012","article-title":"Metabolites and safety: what are the concerns, and how should we address them?","volume":"19","author":"Smith","year":"2006","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2023.115989_bib176","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/bcp.13149","article-title":"Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2\/ALX agonist ACT-389949","volume":"83","author":"Stalder","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib177","series-title":"Aminoimidazole FPR2 Agonists","author":"Perez Heidi","year":"2022"},{"key":"10.1016\/j.ejmech.2023.115989_bib178","series-title":"Derivatives of Cycloalkyl- and Cycloalkenyl-1,2-Dicarboxylic Acid Compounds Having Formyl Peptide Receptor Like-1 (FPRL-1) Agonist or Antagonist Activity","author":"Beard","year":"2011"},{"key":"10.1016\/j.ejmech.2023.115989_bib179","series-title":"Polycyclic Pyrrolidine-2,5-Dione Derivatives as -formyl Peptide Receptor Like-1 (FPRL-1) Receptor Modulators","author":"Beard Richard","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib180","series-title":"Bridged Spiro [2.4] Heptane Derivatives as ALX Receptor And\/or FPRL2 Agonists","author":"Bur","year":"2010"},{"key":"10.1016\/j.ejmech.2023.115989_bib181","series-title":"Bridged spiro[2.4]heptane Ester Derivatives","author":"Bur","year":"2012"},{"key":"10.1016\/j.ejmech.2023.115989_bib182","series-title":"1-(p-tolyl)cyclopropyl Substituted Bridged spiro[2.4]heptane Derivatives as ALX Receptor Agonists","author":"Corminboeuf","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib183","series-title":"Fluorinated Bridged spiro[2.4]heptane Derivatives as ALX Receptor Agonists","author":"Corminboeuf","year":"2013"},{"key":"10.1016\/j.ejmech.2023.115989_bib184","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1016\/j.bmcl.2007.09.043","article-title":"New \u2018chemical probes\u2019 to examine the role of the hFPRL1 (or ALXR) receptor in inflammation","volume":"17","author":"Frohn","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115989_bib185","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1016\/j.ejmech.2010.09.001","article-title":"Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors","volume":"45","author":"Khlebnikov","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115989_bib186","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00894-011-1307-x","article-title":"Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1","volume":"18","author":"Khlebnikov","year":"2012","journal-title":"J. Mol. Model."},{"key":"10.1016\/j.ejmech.2023.115989_bib187","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bcp.2019.04.030","article-title":"Functional and signaling characterization of the neutrophil FPR2 selective agonist ACT-389949","volume":"166","author":"Lind","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115989_bib188","series-title":"Novel Use of a Formyl Peptide Receptor 2\/lipoxin A4 Receptor (FPR2\/ALX) Agonist for Treatment of Heart Failure","author":"Ostrowski","year":"2018"},{"key":"10.1016\/j.ejmech.2023.115989_bib189","first-page":"676","article-title":"Selective FPR2 agonism promotes a proresolution macrophage phenotype and improves cardiac structure-function post myocardial infarction","volume":"6","author":"Garc\u00eda","year":"2021","journal-title":"JACC (J. Am. Coll. Cardiol.): Basic Transl"},{"key":"10.1016\/j.ejmech.2023.115989_bib190","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acsptsci.2c00042","article-title":"Molecular mechanisms of desensitization underlying the differential effects of formyl peptide receptor 2 agonists on cardiac structure-function post myocardial infarction","volume":"5","author":"Lupisella","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.ejmech.2023.115989_bib191","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1126\/science.1109237","article-title":"Transduction of receptor signals by \u00df-arrestins","volume":"308","author":"Lefkowitz","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2023.115989_bib192","doi-asserted-by":"crossref","first-page":"32248","DOI":"10.1074\/jbc.274.45.32248","article-title":"Association of beta-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization","volume":"274","author":"Oakley","year":"1999","journal-title":"J. Biol. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300956X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300956X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:52:36Z","timestamp":1778676756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342300956X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":192,"alternative-id":["S022352342300956X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115989","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The formyl peptide receptors FPR1 and FPR2 as targets for inflammatory disorders: recent advances in the development of small-molecule agonists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115989"}}